Sun Enters Japan Through Divested Novartis Portfolio

30 Mar 2016

Another multinational is shedding a portfolio of non-core mature products in Japan to a generics-focused company, as such drugs come under pricing pressure.

TOKYO - Sun Pharmaceutical Industries Ltd. is entering the Japanese pharma market by acquiring a bundle of 14 established prescription brands from Novartis AG‘s local subsidiary, in an anticipated move that echoes a similar transaction between Takeda Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd. last year.

A subsidiary of the Indian generics-focused firm will buy the therapeutically diverse portfolio - which has combined annual revenues of...